Bioinformatics Analysis of Merkel Cell Carcinoma to identify critical genes and their validation
Merkel Cell Carcinoma (MCC) is a destructive form of neuroendocrine carcinoma that represents the 2nd highest cause of skin cancer related deaths despite being a relatively rare form of cancer. Different risk factors have been associated with MCC such as advancement age, immunosuppression, and ultraviolet light exposure, polyomavirus infection and a current, concurrent or previous diagnosis of Chronic Lymphocytic Leukaemia (CLL). However, the exact mechanism that leads to MCC and its inherent biology is yet to be fully researched and explored. The current treatments for MCC are a combination of surgery and radiation or chemo-radiation. So far, only two drugs have been approved by FDA for the treatment of MCC, with both drugs being immune checkpoint inhibitors. However, the drug approval from FDA was accelerated based on promising results from a relatively small number of patients, which means that the more research and trials are undergoing currently considering the fact that a very small cohort was used for clinical trials. Presently there are no biomarkers indicative of MCC and additional research is essential. With the advent of bioinformatics and microarray technology, in silico approaches pertaining to ‘omics’ data analysis, shall allow identification of hub genes and miRNA to broaden our understanding of MCC biology and their clinical utility.
 Tang CK, Toker C. (1978). Trabecular carcinoma of the skin: an ultrastructural study. Cancer, 42(5), 2311–21.
 Kaae J, Hansen AV, Biggar RJ, Boyd HA, Moore PS, Wohlfahrt J, et al. (2010). Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst, 102 (11), 793-801.
 Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. (2016). Avelumab in patients with chemotherapy refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 17(10), 1374–85.
 Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. (2016). PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med, 374(26), 2542–52.
 Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y,Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. (2014). Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol, 67(1), 3-41.
 Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res., 47(D1):D607-D613.
 Bader GD, Hogue CW. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 13; 4:2.
 Aytes, Alvaro et al. “Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.” Cancer cell vol. 25,5 (2014): 638-651. doi:10.1016/j.ccr.2014.03.017.
 Becker JC. Merkel cell carcinoma. (2010). Ann Oncol, 21(7), 81–85.
 Burack J, Altschuler EL. (2003). Sustained remission of metastatic Merkel cell carcinoma with treatment of HIV infection. J R Soc Med. 9(6), 238–239. doi: 10.1258/jrsm.96.5.238.
 Mariot P, Vanoverberghe K, Lalevee N, Rossier MF & Prevarskaya N. (2002). Overexpression of an alpha 1H (CaV3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J. Biol. Chem, 277(13), 10824–10833.
To ensure uniformity of treatment among all contributors, other forms may not be substituted for this form, nor may any wording of the form be changed. This form is intended for original material submitted to AJCT and must accompany any such material in order to be published by AJCT. Please read the form carefully.
The undersigned hereby assigns to the Asian Journal of Convergence in Technology Issues ("AJCT") all rights under copyright that may exist in and to the above Work, any revised or expanded derivative works submitted to AJCT by the undersigned based on the Work, and any associated written, audio and/or visual presentations or other enhancements accompanying the Work. The undersigned hereby warrants that the Work is original and that he/she is the author of the Work; to the extent the Work incorporates text passages, figures, data or other material from the works of others, the undersigned has obtained any necessary permission. See Retained Rights, below.
AJCT distributes its technical publications throughout the world and wants to ensure that the material submitted to its publications is properly available to the readership of those publications. Authors must ensure that The Work is their own and is original. It is the responsibility of the authors, not AJCT, to determine whether disclosure of their material requires the prior consent of other parties and, if so, to obtain it.
RETAINED RIGHTS/TERMS AND CONDITIONS
1. Authors/employers retain all proprietary rights in any process, procedure, or article of manufacture described in the Work.
2. Authors/employers may reproduce or authorize others to reproduce The Work and for the author's personal use or for company or organizational use, provided that the source and any AJCT copyright notice are indicated, the copies are not used in any way that implies AJCT endorsement of a product or service of any employer, and the copies themselves are not offered for sale.
3. Authors/employers may make limited distribution of all or portions of the Work prior to publication if they inform AJCT in advance of the nature and extent of such limited distribution.
4. For all uses not covered by items 2 and 3, authors/employers must request permission from AJCT.
5. Although authors are permitted to re-use all or portions of the Work in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use.
INFORMATION FOR AUTHORS
AJCT Copyright Ownership
It is the formal policy of AJCT to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of AJCT, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others.
If you are employed and prepared the Work on a subject within the scope of your employment, the copyright in the Work belongs to your employer as a work-for-hire. In that case, AJCT assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.
AJCT requires that the consent of the first-named author and employer be sought as a condition to granting reprint or republication rights to others or for permitting use of a Work for promotion or marketing purposes.
1. The undersigned represents that he/she has the power and authority to make and execute this assignment.
2. The undersigned agrees to indemnify and hold harmless AJCT from any damage or expense that may arise in the event of a breach of any of the warranties set forth above.
3. In the event the above work is accepted and published by AJCT and consequently withdrawn by the author(s), the foregoing copyright transfer shall become null and void and all materials embodying the Work submitted to AJCT will be destroyed.
4. For jointly authored Works, all joint authors should sign, or one of the authors should sign as authorized agent
for the others.
Licenced by :